1Greene HL,Roden DM,Katz RJ,Woosley RL,Salerno DM,Henthorn RW.The Cardiac Arrhythmia Suppression Trial:first CAST then CAST II[J].J Am Coll Carciol,1992,19∶894-898. 被引量：1
2Podrid PJ.Amiodarone:reevaluation of an old drug[J].Ann Intern Med,1995,122∶689-700. 被引量：1
3Roden DM.Pharmacokinetics of amiodarone:implications for drug therapy[J].Am J Cardiol,1993,72∶45F-50F. 被引量：1
4Singh BN,Venkatesh N,Nademanee K,et al.The historical development,cellular electrophysiology,and pharmacology of amiodarone[J].Prog Cardovasc D S,1989,31∶249-280. 被引量：1
5Singh BN,Nademanee K.Amiodarone and thyroid function:clirical implications during antiarrhythmic therapy[J].Am Heart J,1983,106∶857-869. 被引量：1
6Nattle S.Comparative mechanisms of action of antiarrhythmic drugs[J].Am J Cardiol,1993,72(16)∶13F-17F. 被引量：1
7The CASCADE investigators:The Cascade study-randomized anti-arrhythmic drug therapy in survivors of cardiac arrest in Seattle[J].Am J Cardiol,1993,13∶442-449. 被引量：1
9Kowey PR,Levine JH,Herre JM,et al.Randomized,double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent,hemodynamically destabilizing ventricular tachycardia or fibrillation.The Intravenous Amiodarone Multicenter Investigators Group[J].Circulation,1995,92∶3255-3263. 被引量：1
10Scheinman MM,Levine JH,Cannom DS,et al.Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias.The Intravenous Amiodarone Multicenter Investigators Group[J].Circulation,1995,92∶3264-3272. 被引量：1
